Physical exam • HR - 90/min RR - 20/min BP - 130/70 • Lung - ↓ Rt. base • Abdonminal distension / Clinical ascites • Abdominal / Pelvic mass
Case report
Ovarian cancer
Ami Fishman, M.D.
Meir Hospital - Sapir Med Center
Kfar-Saba, Israel
10.2001
57y-o, G3P2,
upper abdominal pain ⊕ discomfort - 3mo, abdominal girth increase ~ 1mo
◊
???
57y-o, G3P2,
upper abdominal pain + discomfort - 3mo, abdominal girth increase ~ 1mo
↓
H
History
• General
• Gynecologic - Reproductive
• Familial
Physical exam
• HR - 90/min RR - 20/min BP - 130/70
• Lung - ↓ Rt. base
• Abdonminal distension / Clinical ascites
• Abdominal / Pelvic mass
work-up
↓
???
work-up
↓
Blood:
- CBC + SMA + Coag. profile
- Tu markers
- Genetics / molecular
work-up
↓
Imaging:
-Chest X-ray
- Abdominal CT
- U/S
- GITr/GUTr
- Mammography
Chemotherapy
Neo-adjuvant chemotherapy
- Taxol + Carboplatin
- No. of cycles?
- Interval debulking
- Response parameters
Ovarian Ca - advanced disease Treatment
Standard of care:
↓
Primary surgical cytoreduction followed by platinum-based chemotherapy
Ami Fishman, M.D.
Surgery
• Objective - advanced disease - early disease
Pre-op work-up
- Routine blood + Cross & Type
- Prophylactic heparin
- Anesthesia clearance
- G.I.Tr. Prep
• mechanical
• antibiotics
Surgery
Debulking
- rational
- definitions
- procedures
Ovarian Ca - advanced disease
Optimal Residual Disease
better prognosis
no residual tumor
< 0.5 cm
0.5-1.5 cm
Ami Fishman, M.D.
Surgery
• Objective - early disease
• Staging - rational
- procedures
Ovarian Ca - advanced disease Treatment
~ 40 - 60%
Rate of achieving optimal primary cytoreductive surgery
Ami Fishman, M.D.
Adjuvant chemotherapy
• Definitions
• Protocol
• Combinations
Adjuvant chemotherapy
• Taxol + Carboplatin
• Side effects
- Systems
- Limiting
• Routine F/U
Adjuvant chemotherapy
• Carboplatin (Calvert AUC= 6-7)
• Taxol (175 mg/m2)
• x6 courses q3 weeks
Ami Fishman M.D.
Adjuvant chemotherapy
Platinum + Taxol
• Response Rate (clinical) = 70-80%
• end of RX - ???
• Platinum sensitive
• Platinum resistant
Ami Fishman M.D.
Chemotherapy
• Response definitions:
- Complete
- Partial
- Stable disease
- Progression
15 mo following last chemotherapy cycle
Asymptomatic
CA-125 = 10/2000 => 17
01/2001=> 67
◊
???
Elevated CA-125
• Asymptomatic patient
- Evaluate disease
To treat or not to treat??
2nd line chemotherapy
• Chemo-sensitive
• Chemo-resistant
2nd line chemotherapy
• Re-induction
• Others - old agents
- new agents
• High dose
• Intra-peritoneal
• Research protocols
Research protocol
• Phase I/II/III
• protocol end points
37 y-o
7cm ovarian complex cyst
↓
• Larparoscopy
↓
Procedures:
• peritoneal washing for cytology
• Frozen section
Frozen section
==> LMPT
↓
• ???
Procedures:
• USO
• Surgical staging:
omentectomy + peritoneal biopsies
+ retrop. LN sampling
37 y-o, Laparosscopic USO
Final histology (after 10 days) ==>
Ovarian Ca
↓
???
Review/confirm histology
Consider:
- grade
- age & reproductive plan
- site /experience of surgeon at 1st procedure
- referral to Gyn-Onc
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More